19,986 Shares in Pfizer Inc. $PFE Purchased by Chesapeake Capital Corp IL

Chesapeake Capital Corp IL acquired a new position in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 19,986 shares of the biopharmaceutical company’s stock, valued at approximately $498,000.

Several other large investors also recently bought and sold shares of PFE. Vanguard Group Inc. boosted its position in Pfizer by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after purchasing an additional 7,031,162 shares during the last quarter. State Street Corp boosted its position in Pfizer by 0.9% in the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after purchasing an additional 2,786,098 shares during the last quarter. Northern Trust Corp boosted its position in Pfizer by 1.4% in the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock worth $1,631,225,000 after purchasing an additional 869,175 shares during the last quarter. Fisher Asset Management LLC boosted its position in Pfizer by 1.9% in the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock worth $1,255,860,000 after purchasing an additional 897,786 shares during the last quarter. Finally, Legal & General Group Plc boosted its position in Pfizer by 8.6% in the third quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock worth $1,063,565,000 after purchasing an additional 3,296,415 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Scotiabank initiated a Buy view on Pfizer, adding to recent analyst confidence in the stock. Pfizer (PFE) Receives a Buy from Scotiabank
• Positive Sentiment: Erste Group slightly raised its FY2026 EPS estimate for Pfizer, reinforcing expectations that earnings remain stable and in line with consensus.
• Positive Sentiment: Recent coverage highlighted Pfizer’s Q1 beat, better-than-expected sales, and progress in its oncology pipeline, suggesting the company’s newer drugs are becoming more important to the investment story. How Pfizer’s Q1 Beat, Oncology Wins and Patent Deals At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer’s dividend remains a major draw for income investors, and a recent article argued that the high yield is still supported by management’s execution and cash flow. Pfizer’s 6.5% Dividend Yield Looked Too Good to Be True — but Management Just Silenced the Skeptics
• Neutral Sentiment: Pfizer is continuing to advance a new Phase 1 cancer trial, which signals ongoing investment in oncology but is still too early to materially change near-term financial results. Pfizer’s New Phase 1 Cancer Trial Signals Fresh Oncology Push for PFE Investors
• Neutral Sentiment: Pfizer was also mentioned in a cancer-care industry recognition announcement, but the item is mostly reputational and unlikely to move the stock on its own.
• Negative Sentiment: Pfizer halted an early-stage cancer study, and investors may view the termination as a small setback for its oncology pipeline, even if the financial impact is limited. Pfizer Terminates Early-Stage Cancer Trial: What It Means for PFE Investors
• Negative Sentiment: Pfizer ended another early-stage lymphoma combination trial, which adds to concerns that some pipeline programs may not advance as hoped. Pfizer Ends Early-Stage Lymphoma Combo Trial, Trimming a Small Piece of Its Oncology Upside

Wall Street Analyst Weigh In

PFE has been the topic of several research reports. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Wednesday, February 4th. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a research report on Monday, March 2nd. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday. UBS Group raised their target price on Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research report on Monday, April 13th. Finally, Citigroup raised their target price on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $28.74.

Pfizer Stock Down 3.1%

NYSE PFE opened at $25.65 on Friday. The stock’s 50 day moving average is $27.14 and its 200 day moving average is $26.16. The company has a current ratio of 1.25, a quick ratio of 0.87 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 12 month low of $21.97 and a 12 month high of $28.75. The stock has a market cap of $146.17 billion, a PE ratio of 19.58 and a beta of 0.35.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the previous year, the firm earned $0.92 EPS. The firm’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts predict that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio is currently 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.